Oppenheimer analyst Hartaj Singh initiated coverage of Entrada Therapeutics (TRDA) with an Outperform rating and $22 price target. Entrada is advancing lead program ENTR-601-44 in the clinic for patients with DMD amenable to exon 44 skipping and the firm is “intrigued” by the company’s Endosomal Escape Vehicle delivery platform for a wide range of therapeutic moieties, the analyst tells investors. The firm, which awaits first clinical data from Phase 1 healthy volunteers trial of ENTR-601-44 in the second half of 2024, adds that Entrada’s deal with Vertex Pharmaceuticals (VRTX) in DM1 gives it “conviction for platform valuation.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TRDA:
- Entrada Therapeutics promotes Dowden to President
- Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101
- Entrada Therapeutics expects cash to fund requirements through 2025